BMS Is Printing Money Right Now. The Clock Is Ticking.
Bristol Myers Squibb just crushed Q2 estimates and hiked its 2026 forecast by billions, thanks to a blood thinner that won't quit and a new drug lineup firing on all cylinders. There's just one problem: the biggest patent cliff in pharma history is about 18 months away.
Imagine you're throwing the best party of your life, and you already know the landlord is evicting you next year. That's basically where Bristol Myers Squibb sits right now.
The company just posted Q2 2026 results that crushed expectations on nearly every line. Revenue hit $13 billion, up 6% year over year. Adjusted earnings per share came in at $2.04, walloping Wall Street's estimate of $1.59. And then BMS did something that made investors sit up straight: it raised its full-year 2026 guidance. Not by a little. By a lot.
The stock climbed roughly 2.4% on the news. A solid day, but not exactly a moonshot. And that measured reaction tells you everything about where this story is really headed.
The Numbers Behind the Swagger
Let's start with what went right. BMS bumped its 2026 revenue guidance from $46–$47.5 billion to $49–$50 billion. Its earnings forecast jumped from $6.05–$6.35 per share to $6.75–$7.00. For context, Wall Street consensus had been sitting around $6.27. The new midpoint is roughly 8% above where analysts thought BMS would land.
The company's so-called Growth Portfolio (think newer drugs, not the legacy cash cows) brought in $7.6 billion in Q2 alone, up 15% from last year. That portfolio now accounts for about 60% of total sales, which is a quiet but massive shift in the company's center of gravity.
But the real headline? Eliquis, the blockbuster blood thinner that was supposed to be coasting into sunset mode, just posted $4.48 billion in quarterly revenue. That's a 22% jump and well above the $4.06 billion analysts expected. BMS now thinks Eliquis will grow 20–25% for the full year, up from its earlier call of 10–15%.
Eliquis is the dominant leader in new U.S. prescriptions in its drug class. It's less of a product and more of a franchise at this point.
The New Kids Are Showing Up
What makes this earnings report more interesting than a typical "big pharma beats estimates" story is the breadth of the outperformance. This wasn't just an Eliquis story.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Reblozyl, a treatment for anemia linked to a blood disorder called MDS, pulled in $735 million in Q2, topping expectations of $664 million. It's already running at an annualized pace above $2 billion.
Camzyos, a heart medication for a condition called obstructive hypertrophic cardiomyopathy (basically, an abnormally thick heart muscle that blocks blood flow), hit $416 million versus the $365 million Wall Street expected. Breyanzi, a CAR-T cell therapy for certain blood cancers, brought in $484 million against estimates of $422 million. Breyanzi has now crossed the $1 billion annualized sales mark and is growing at over 40% year over year.
Even Opdualag, the melanoma combo therapy that's become standard of care in first-line treatment, posted solid gains.
The message from management: this is not a one-trick company anymore.
The Eviction Notice
Now for the part that keeps BMS investors up at night.
Eliquis lost patent protection in Europe around May 2026. Generics are already entering the market there. And the U.S. patent cliff? That's expected to hit around 2027–2028, with the biggest commercial impact modeled in 2028 when pharmacy-level generic substitution and insurance formulary changes kick in hard.
The projections are brutal. One analyst forecast sees global Eliquis revenue falling from roughly $14.4 billion in 2025 to about $205 million by 2031. That's a 98.6% decline. BMS itself has told investors to expect a $1–2 billion drop in 2027 just from European generic pressure.
And Eliquis isn't even the only problem. Revlimid, once BMS's biggest drug, is already hemorrhaging revenue to generics. Opdivo, the flagship cancer immunotherapy, faces its own patent pressures in the coming years. Together, Revlimid, Opdivo, and Eliquis generated roughly $28 billion in 2024 revenue. By 2030, an estimated 47% of BMS's total revenue is at risk from patent expirations.
That's not a speed bump. That's a canyon.
Running to Stand Still
BMS's strategy for surviving the cliff has three parts, and none of them involve panic.
First, cost cuts: the company is targeting $2 billion in annual expense reductions by the end of 2027. Second, scaling the growth portfolio: drugs like Reblozyl, Camzyos, Breyanzi, Opdualag, and Sotyktu (an immunology drug with pivotal data coming in lupus and Sjogren's disease) need to collectively fill a multi-billion-dollar hole. BMS expects readouts from six pivotal assets in 2026 alone, and the company's long-term plan calls for 10 new drug launches and 30 label expansions over the next five years.
Third, dealmaking. When you're staring down a revenue gap this large, you can't just R&D your way out. You buy pipelines. BMS has been active on the business development front, and it will need to stay that way.
How BMS Stacks Up Against Its Peers
BMS isn't alone in facing the cliff, but it may have the steepest fall ahead. Merck is dealing with generic entry for its diabetes franchise (Januvia/Janumet) starting mid-2026, and faces a massive Keytruda reckoning around 2028. Merck's hedge? A subcutaneous reformulation called Keytruda Qlex, essentially a new, patentable version of its biggest drug. It's clever and could preserve billions a year in revenue.
Pfizer, meanwhile, is losing ground on Xeljanz and Xtandi, with roughly $3–3.5 billion in annual sales at risk. Its playbook leans heavily on large acquisitions to plug the gaps.
BMS, by contrast, doesn't have a single transformative reformulation play. Its survival depends on a portfolio approach: lots of newer drugs, all growing, collectively replacing what the legacy brands lose. It's the difference between having one fire extinguisher and having a dozen garden hoses. Both can work, but one leaves a lot less margin for error.
The Bottom Line
Q2 2026 was a genuinely impressive quarter for BMS. The guidance raise was real, the Growth Portfolio is delivering, and Eliquis is squeezing out every last dollar before the generics arrive. Wall Street noticed; analysts came in with a Moderate Buy consensus and an average price target around $62.65 heading into earnings, and the results gave the bulls something to work with.
But the market's muted 2.4% reaction tells the deeper story. Investors aren't paying a premium for earnings that might not exist in three years. BMS is running a race against time: can it build a new revenue engine fast enough to replace the old one before it falls apart?
Right now, the answer is "maybe." And in pharma, "maybe" is about as good as it gets.
Deals & M&A
4 min read
AstraZeneca Just Spent $2.1 Billion to Pick a Fight With Merck
AstraZeneca signed a $2.1 billion licensing deal with Sino Biopharmaceutical for a COPD drug designed to challenge Merck's blockbuster Ohtuvayre. With stronger early lung function data and AstraZeneca's massive respiratory salesforce behind it, the PDE3/PDE4 market just became a two-horse race.
